TheraVac Biologics

Executive Summary

TheraVac Biologics is a private biotechnology company pioneering novel immunotherapies for chronic and neurodegenerative diseases. Its core technology leverages virus-like particles (VLPs) to display immunogenic peptides, creating vaccines that target disease-causing protein aggregates and inflammatory pathways. The lead programs focus on Alzheimer's disease and frontotemporal dementia, two devastating CNS conditions with high unmet medical need. By harnessing the immune system to clear toxic protein aggregates, TheraVac's approach could offer disease-modifying benefits beyond symptomatic treatments. Founded in 2016 and based in San Diego, the company operates at the preclinical stage, with no disclosed funding or clinical pipelines yet. Given the complexity of CNS diseases and the early stage of development, significant milestones are needed to validate the platform and advance toward clinical trials.

Upcoming Catalysts (preview)

• 2027Preclinical proof-of-concept data for Alzheimer's vaccine candidate25% success
• 2026Series A financing round to advance lead programs into IND-enabling studies30% success
• 2027Strategic partnership with a larger biopharma for CNS vaccine development20% success